Neurologia | 2021

Nutritional status assessment in Alzheimer disease and its influence on disease progression.

 
 
 
 
 
 
 
 

Abstract


INTRODUCTION\nNutritional deficiencies are frequent in Alzheimer disease (AD), even in early stages. Nutritional impairment (NI) may be associated with faster disease progression. The objective of this study was to describe the frequency of NI and the associated risk factors at the time of diagnosis and to analyse its influence on subsequent progression.\n\n\nMETHODS\nWe performed a prospective, multicentre, observational study of patients recently diagnosed with prodromal AD (pAD) or dementia due to AD (ADd). Two clinical assessments were conducted over a period of 18 months. The Mini Nutritional Assessment test (MNA; score range, 0-30; cut-off point for NI, < 24) was used to estimate nutritional status. Progression was defined as an increase of ≥ 3 points on the Clinical Dementia Rating-sum of boxes test.\n\n\nRESULTS\nThe sample included 50 patients with pAD (mean [standard deviation] age, 76.1 [5.3] years; 68% women), and 127 with ADd (80 [5.9] years; 72.4% women). A total of 141 (79.7%) completed both evaluations. The prevalence of NI was 28.2% (24% for pAD, 29.9% for ADd; P\xa0=\xa0.43), with the majority (92%) at risk of malnutrition. NI was associated with female sex (odds ratio [OR]: 4.2; 95% confidence interval [CI]: 1.7-10.5; P\xa0<\xa0.001) and greater behavioural involvement (OR: 5.8; 95% CI: 2.6-12.7; P\xa0<\xa0.001). A larger proportion of patients with progression was observed among those with NI than among those with normal nutritional status (50% vs 28.7%, P\xa0<\xa0.05; ADd: 53.6% vs 31.8%, P\xa0<\xa0.05; pAD: 41.7% vs 22.9%, P\xa0=\xa0.21). Greater cognitive impairment (OR: 2.1; 95% CI: 1.03-4.4; P\xa0<\xa0.05) and NI (OR: 2.4; 95% CI: 1.1-5.1; P\xa0<\xa0.05) were independent risk factors for disease progression.\n\n\nCONCLUSIONS\nNI is highly prevalent in patients with AD. Assessing nutritional status at the time of diagnosis may enable identification of patients at greater risk of disease progression.

Volume None
Pages None
DOI 10.1016/j.nrleng.2019.11.006
Language English
Journal Neurologia

Full Text